Introduction
============

Data from population-based registries collected by the National Central Cancer Registry of China (2009--2011) showed that lung cancer has the highest incidence and is the leading cause of cancer death in China. The results indicated that an estimated 733,300 new lung cancer cases and 610,200 lung cancer deaths would occur in China in 2015.[@b1-cmar-10-115],[@b2-cmar-10-115] Generally, non-small cell lung cancer (NSCLC) and small cell lung cancer are the major pathology subtypes of lung cancer.[@b3-cmar-10-115] NSCLC comprises almost 80%--85% of all lung cancer cases.[@b3-cmar-10-115],[@b4-cmar-10-115] It is reported that activating mutation of EGFR could control cellular proliferation and survival of cancer cells.[@b5-cmar-10-115] Point mutations of exon 21 (Leu858Arg) and exon 19 (in-frame) deletions are the most common activating mutations of EGFR, which constitutes more than 90% of known activating EGFR mutations.[@b6-cmar-10-115] The frequency of EGFR mutation among Caucasian NSCLC populations is approximately 20%, compared with 60%\~70% in never-smoking, Asian, adenocarcinoma lung cancer patients.[@b7-cmar-10-115] EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib,[@b8-cmar-10-115],[@b9-cmar-10-115] gefitinib,[@b10-cmar-10-115],[@b11-cmar-10-115] afatinib[@b12-cmar-10-115],[@b13-cmar-10-115] or icotinib,[@b14-cmar-10-115] have led to dramatic improvement in progression-free survival (PFS) compared to standard chemotherapy for lung cancer patients with specific EGFR mutations (p.L858R or exon 19 deletions).

Although the superiority of first-line gefitinib and erlotinib (the "first generation" EGFR TKIs) over standard chemotherapy has been established in several clinical trials, most patients who had responded to EGFR TKIs acquired resistance to them and had disease progression within 10\~16 months.[@b15-cmar-10-115] Of those resistance cases, 50%\~65% developed a second EGFR mutation, T790M. This mutation is a critical amino acid that lies within the ATP-binding pocket of EGFR, when it occurs in cis with the original drug-sensitive EGFR mutation, it could reduce drug affinity of the kinase domain compared with cellular ATP.[@b8-cmar-10-115],[@b16-cmar-10-115]--[@b18-cmar-10-115] Neither the "first generation" EGFR TKIs nor the "second generation" EGFR TKIs (neratinib, afatinib, and dacomitinib) could overcome the resistance to EGFR TKIs, which is caused by the EGFR T790M mutation.[@b19-cmar-10-115] The "third generation" EGFR TKIs (osimertinib, CO-1682, HM61713 and AC0010) have been demonstrated to irreversibly bind to the sensitive mutation form of EGFR (L858R, delE746-A750) and the gatekeeper mutation (T790M).[@b20-cmar-10-115]--[@b22-cmar-10-115] Specifically, osimertinib has been approved by the US Food and Drug Administration (FDA) in 2015 for NSCLC patients with EGFR T790M mutation,[@b23-cmar-10-115] and by the China Food and Drug Administration (CFDA) in 2017. The Phase III trial, AURA3, recruited 419 patients with T790M+ advanced NSCLC, the median duration of PFS with osimertinib was 10.1 months, 5.7 months longer than with platinum therapy plus pemetrexed.[@b24-cmar-10-115]

Recently, ctDNA has emerged as a specific and sensitive biomarker for EGFR variants' detection.[@b25-cmar-10-115],[@b26-cmar-10-115] Minimal invasion is the most prominent advantage for ctDNA test. Another advantage, comprehensive analysis of the tumor heterogeneity, makes ctDNA test more popular for tumor research.[@b27-cmar-10-115]--[@b29-cmar-10-115] However, the abundance of ctDNA varies from 0.01% to 67% for patients with different kinds of cancers or progression stages.[@b26-cmar-10-115],[@b30-cmar-10-115],[@b31-cmar-10-115] Thus, there is an urgent need for a standardized, sensitive method for ctDNA testing. The non-digital platforms (ARMS and Cobas^®^) and the digital platforms (BEAMing digital PCR, Droplet digital PCR and next generation sequencing \[NGS\]-based methods) have been commonly used for analyzing the EGFR mutations in plasma ctDNA.[@b32-cmar-10-115],[@b33-cmar-10-115] AURA I reported that sensitivity of EGFR T790M plasma detection (by BEAMing) was 70%, compared with tissue genotyping (by Cobas). Approximately 45% false-negative plasma genotyping patients have significant outcomes (median PFS, 9.3 months) with osimertinib, according to T790M+ tissue genotyping.[@b34-cmar-10-115] In this study, we introduced a super sensitive ctDNA T790M detection method through QuantStudio™ 3D Digital PCR System platform, which can detect low levels of somatic T790M alterations in plasma of patients. According to 3D digital PCR approach, the reaction is divided into 20,000 individual partitions, and the absolute copy number is calculated based on statistical interpretation of the number of partitions where the target mutation alleles have been detected, compared to those where wild-type alleles have been detected. It also gives the chance to detect T790M before EGFR TKI exposure, providing more accurate molecular diagnostic information to advanced NSCLC patients.

Methods
=======

Experimental design
-------------------

Plasma samples were collected from 119 NSCLC patients during January 2015 to September 2016, separated from 8--10 mL anticoagulant venous blood. All EGFR T790M mutations were detected using QuantStudio™ 3D Digital PCR System from plasma DNA. Then we selected T790M frequency \<2.5% and partial T790M- samples, which were used to do ARMS-PCR single blind verification. Limited by the remaining amount of ctDNA, we only verified 25 samples; including four samples which were verified by NGS at the same time. The sensitivity and specificity of plasma EGFR T790M mutation genotyping by 3D Digital PCR were analyzed. This study was approved by the Medical Ethics Committee of Peking University Cancer Hospital and performed according to the Declaration of Helsinki principles. All patients signed informed consent for their samples to be used in a future study. All clinical data and samples were received anonymously.

ctDNA extraction
----------------

Peripheral blood samples were collected into BCT-EDTA tubes (Streck, Omaha, NE, USA). Plasma was isolated from blood by centrifuging at 1,600 *g* for 10 minutes at 4°C. Then the plasma was further centrifuged at 16,000 *g* for 10 minutes at 4°C, and was then stored at 80°C until ctDNA extraction. Plasma ctDNA was extracted from 2 mL of plasma from each patient with the QIAamp Circulating Nucleic Acid kit (Qiagen NV, Venlo, the Netherlands), following the manufacturer's instructions.

Plasma ctDNA EGFR T790M detection
---------------------------------

We used three methods to detect plasma ctDNA T790M in this research, 3D Digital PCR, NGS, and ARMS-PCR. We purchased all 3D Digital PCR reagents from Thermo Fisher Scientific (Waltham, MA, USA), custom ordered primers (T790M-F: 5′-GCATCTGCCTCACCTCCACC; T790M-R: 5′-ACCAGTTGAGCAGGTACTGGGAGC) and probes (T790M-P1(FAM):5′-AGCTCATCATGCAGCTCAT; WT-P2(VIC): 5′-AGCTCATCACGCAGCTCAT) from Life Technologies (Thermo Fisher Scientific), and performed the 3D Digital PCR analysis on a QuantStudio™ 3D Digital PCR System. We optimized the experimental process, the lowest detection rate of plasma T790M is 0.04%, stable detection frequency of plasma T790M is 0.1%, as previously published.[@b35-cmar-10-115] The final 15 μL of TaqMan PCR reaction mixture was made up in the following way: 7.5 μL 2× QuantStudio™ 3D Digital PCR Master Mix, 0.75 μL 20× TaqManAssay (primer/probe mix), 6.75 μL diluted DNA (25 ng), and then loaded into the QuantStudio™ 3D Digital PCR Chip, which has 20000 mini-chambers. To perform the PCR using the ProFlex™ 2× Flat PCR System, thermal cycling profile was 10 minutes of incubation at 96°C, followed by 39 cycles of 56°C for 2 minutes, 98°C for 30 seconds, 56°C for 2 minutes, and then 4°C hold. We used the QuantStudio™ 3D Digital PCR instrument to read the chip. The subsequent analysis was performed with the QuantStudio 3D Analysis Suite Software.

Plasma ctDNA was sequenced using paired-end strategy on an Illumina HiSeq platform (Illumina, San Diego, CA, USA), as previously published.[@b36-cmar-10-115] A KAPA Hyper Prep kit (Kapa Biosystems Inc., MA, USA) was used to construct the library. Then the prepped libraries were hybridized with SureSelectQXT Target Enrichment System (Agilent Technologies) to capture the targeted sequences. The concentration of each library was quantified using a QPCR NGS library quantification kit (Agilent Technologies, Santa Clara, CA, USA). After sequencing, the raw data were analyzed by self-developed analytical software. Every somatic mutation identified in ctDNA was checked by Integrative Genomics Viewer software and Samtools software.

ADx-ARMS (amplification refractory mutation system) EGFR mutation kit (Amoy Diagnostics, Xiamen, China) was used, and all experiments and genotype calling were performed following the manufacturer's instructions.

Statistical analysis
--------------------

The statistical data were analyzed with SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA). The McNemar's test and Fisher's exact test were used to compare the consistency of plasma T790M mutation result between 3D digital PCR and ARMS-PCR.

Statistical figures were done with GraphPad Prism 6.0 software (GraphPad Software, Inc., La Jolla, CA, USA).

Results
=======

Clinico-morphological characteristics of patients
-------------------------------------------------

Peripheral blood samples obtained from 119 NSCLC patients, aged between 31 and 91 were tested in this study. Patients' clinical characteristics are listed in [Table 1](#t1-cmar-10-115){ref-type="table"}. Sixty females and 59 males participated in this study cohort, of whom 82 were diagnosed with stage III--IV NSCLC. A total of 106 of 119 patients (89%) had adenocarcinoma or mixed histology. Treatment experienced patients accounted for 86.6% (103 of 119) of the total patients, and 92.2% (95 of 103) of them received EGFR TKIs treatment and reached the drug resistant state. There were also 16 treatment naïve patients in our study, who were recruited for detecting the primary EGFR T790M mutation.

Plasma EGFR T790M detection results by 3D Digital PCR
-----------------------------------------------------

We performed a 3D Digital PCR analysis of 119 plasma ctDNA samples, to detect T790M mutation alleles from NSCLC patients. The percentage of T790M-mutant allele frequency in the 119 plasma samples was shown in [Table 1](#t1-cmar-10-115){ref-type="table"}, and the ratios of mutant allele frequency were summarized in [Figure 1](#f1-cmar-10-115){ref-type="fig"} and [Table 2](#t2-cmar-10-115){ref-type="table"}. The overall plasma EGFR T790M mutation rate in Chinese NSCLC patients was 52.94%, notable, eight of the 16 treatment naïve patients were found to be plasma T790M+. No statistical difference was found between the pretreatment T790M mutation and clinical parameters such as gender, histologic type, or tumor stage. Although there is a tendency that patients treated with erlotinib are more likely to acquire resistance of T790M mutation compared with gefitinib or icotinib, no statistical difference was found.

Among the 63 positive cases, three samples (4.76%) presented at a low ratio (\<0.1%) that could be detected with the 3D Digital PCR system. The median mutant allele frequency of plasma T790M was 1.09%. A total of 19 samples (30.16%) presented at a median ratio (\<5%), and 16 samples (25.4%) presented at a high ratio (\>5%) in this study.

Ultra-low plasma EGFR T790M detected by 3D digital PCR
------------------------------------------------------

To demonstrate the sensitivity of our 3D Digital PCR assay to detect plasma EGFR T790M, we compared the result of ctDNA extracted from one plasma sample detected by our assay with the CFDA-approved ADx-ARMS EGFR mutation kit. Limited by the amount of 10 mL extracted from a patient's blood ctDNA, we selected 17 samples which had T790M frequency \<2.5% and eight samples which were T790M-, to do ARMS-PCR single blind verification. We used McNemar's test to analyze whether the results between 3D Digital PCR and ARMS-PCR were consistent, the results showed that: *P*=0.0002, indicating that the results of the two methods were inconsistent. Then we analyzed the consistency of T790M+ samples and T790M-samples between the two methods separately using Fisher's exact test, the results showed that: *P*=0.0001, indicating that those were inconsistent, and the number of 3D Digital PCR T790M+ samples detected was much more than ARMS-PCR, which demonstrated the sensitivity of our 3D Digital PCR assay.

Four samples were enough for verification by Illumina HiSeq sequencer as a third verification method. The general comparison results were shown in [Tables 3](#t3-cmar-10-115){ref-type="table"} and [4](#t4-cmar-10-115){ref-type="table"}; we also enumerate the test results of ten of the samples using the three platforms in [Table 5](#t5-cmar-10-115){ref-type="table"}. Among the selected 17 positive cases, ten samples presented at a ratio of \<0.5%, and seven samples presented at a ratio of \<2.5%. However, only three samples were identified as positive for the EGFR T790M mutation by ARMS-PCR, namely, P6 (mutant allele frequency of T790M detected by 3D Digital PCR was 1.09%), P7 (mutant allele frequency of T790M detected by 3D Digital PCR was 2.09%), and P8 (mutant allele frequency of T790M detected by 3D Digital PCR was 2.21%). It is worth mentioning that sample P9 was identified as T790M- by ARMS-PCR, however, mutant allele T790M was detected by 3D Digital PCR at a frequency of 2.05%, suggesting that our 3D Digital PCR assay is more sensitive for detecting plasma T790M mutation. Samples P1--P4 was identified as T790M+ by both NGS and 3D Digital PCR, typically P1--P3 presented at a low ratio (\<0.5%), suggesting the specificity of our 3D Digital PCR assay.

Discussion
==========

In the treatment process of EGFR-TKIs, most patients will eventually become resistant to EGFR-TKIs therapy. As we know, T790M mutation of EGFR gene is the most important mechanism of EGFR-TKIs drug resistance. More than 50% EGFR-TKIs drug resistance is caused by T790M mutation.[@b17-cmar-10-115],[@b37-cmar-10-115] It is reported that T790M mutation in peripheral blood occurred earlier than the disease progression.[@b38-cmar-10-115] It is beneficial in terms of clinical decisions for patients, if T790M mutation is detected early. In addition, requiring additional biopsy tissue causes difficulties for those with advanced or recurring lung cancer. Because of tumor heterogeneity and the fact that biopsy is usually done at single site, there may be homogeneity in the genetic information from patient plasma.[@b39-cmar-10-115] Compared with tumor tissue, detecting T790M mutation in the plasma ctDNA of lung cancer patients will have great advantages.[@b40-cmar-10-115] Detecting T790M mutation in plasma is already a focus of research. There are some studies which used different assays for detecting EGFR gene status in plasma, including DHPLC, ARMS-PCR, and ddPCR.[@b41-cmar-10-115] 3D Digital PCR system is a relatively new technology of ddPCR.[@b42-cmar-10-115] It requires no external calibrators for measuring the absolute and relative copy numbers of target DNA. Rapid microfluidic analysis of thousands of droplets per sample makes ddPCR practical for routine use. 3D digital PCR extends the performance of existing TaqMan assays, enabling applications that benefit from higher sensitivity, precision, or absolute quantification. In our study, in the group of 119 plasma ctDNA samples from NSCLC patients, 63 (52.9%) were found to have T790M gene mutation by 3D digital PCR. Among the 63 positive cases, three samples (4.76%) presented at a low ratio (\<0.1%) that could be detected with the 3D digital PCR system. The median plasma T790M mutation frequency is 1.09%. Our T790M mutation frequency data according to ctDNA is consistent with the frequency (more than 50%) according to tissue sampling, which was shown in previous studies of patients after disease progression and treatment with EGFR TKIs.[@b43-cmar-10-115],[@b44-cmar-10-115] Therefore, our results show that 3D Digital PCR system is a sensitive method to detect EGFR T790M status in plasma of advanced NSCLC patients.

Ishii et al detected T790M status in EGFR-TKI-resistant patients by digital PCR. The result showed the sensitivity was 81.8%, and the specificity was 85.7%. The consistency with the paired tissue sample detection was 83.3%.[@b45-cmar-10-115] Thress et al used four platforms respectively for detecting EGFR mutations in plasma ctDNA.[@b33-cmar-10-115] The platforms included two non-digital platforms (Cobas^®^ and ARMS-PCR) and two digital platforms (BEAMing digital PCR and Droplet digital PCR). For the T790M mutation, the sensitivity and specificity was 73% and 67%, respectively, with the Cobas^®^ EGFR Mutation Test, and 81% and 58%, respectively, with BEAMing PCR. The research finding suggested that the Cobas^®^ EGFR Mutation Test and BEAMing PCR demonstrate a high sensitivity for T790M mutation detection. Zheng et al's research showed that T790M ctDNA mutation in plasma was detected in 55 (47%) of the 117 patients, using the ddPCR method.[@b46-cmar-10-115] The results demonstrated that the overall concordance rate of T790M testing between the paired tumor tissue and plasma was 88.00% (22/25). The sensitivity and specificity of plasma T790M testing by ddPCR assay was 81.25% (13/16) and 100.00% (9/9), respectively. Therefore, according to the research findings, ddPCR is a potential method with higher precision, sensitivity, and accuracy for detecting EGFR gene T790M mutation in plasma compared with ARMS assay. In our study, we compared the 3D Digital PCR with the ARMS-PCR method for detecting T790M mutation. Our result showed only three plasma samples were identified as positive for the EGFR T790M mutation by ARMS-PCR in 17 T790M mutation positive cases detecting by 3D Digital PCR. These 17 positive samples included ten samples which presented at a ratio of \<0.5%, and seven samples that presented at a ratio of \<2.5%. Meanwhile four positive plasma samples were verified by NGS platform. Our data illustrated that 3D Digital PCR assay was more sensitive and specific than ARMS-PCR for detecting T790M mutation in plasma samples.

Regarding limitations of our study, firstly, we collected 8--10 mL peripheral blood from every patient according to their clinical statuses. Plasma ctDNA levels vary greatly among different patients. Because of the limitation of plasma sample volume, we did not compare all the samples with 3D Digital PCR and ARMS assay. Meanwhile, only four plasma samples were enough to be validated by NGS method. Secondly, we did not obtain corresponding tumor tissues to detect the T790M status because it is difficult to obtain biopsies from advanced NSCLC patients. So, we could not compare T790M status in plasma ctDNA with tumor tissues.

Conclusion
==========

We evaluated a novel 3D Digital PCR assay for detecting EGFR gene T790M mutations in plasma samples of NSCLC patients. Our study indicated the great advantages of 3D Digital PCR regarding EGFR T790M mutation after resistance to EGFR-TKIs. 3D Digital PCR technology has more sensitivity and specificity than traditional PCR methods. 3D Digital PCR is a suitable method for plasma ctDNA testing in NSCLC patients with EGFR-TKI resistance.
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###### 

Clinico-morphological characteristics of patients

  Clinico-morphological characteristics of patients   Number        Plasma T790M+ rate
  --------------------------------------------------- ------------- --------------------
  **Gender**                                                        
  Male                                                59 (49.6%)    32 (54.2%)
  Female                                              60 (50.4%)    31 (51.7%)
  **Age**                                                           
  Median (range)                                      63 (31--91)   
  **Histology**                                                     63 (52.9%)
  Adenocarcinoma                                      100 (84.0%)   55 (55%)
  Squamous cell carcinoma                             3 (2.5%)      1 (33.3%)
  Adenocarcinoma mixed small cell lung cancer         1 (0.8%)      0
  Adenocarcinoma mixed squamous cell carcinoma        2 (1.7%)      0
  Unknown                                             13 (10.9%)    7 (53.8%)
  **Tumor stage**                                                   63 (52.9%)
  II                                                  1 (0.8%)      0
  III                                                 8 (6.7%)      3 (37.5%)
  IV                                                  74 (62.2%)    45 (60.8%)
  Unknown                                             36 (30.3%)    15 (41.7%)
  **Treatment history**                                             63 (52.9%)
  Treatment naïve patients                            16 (13.4%)    8 (50.0%)
  Treatment experienced patients                      103 (86.6%)   55 (53.4%)
  **Targeted therapy**                                95 (79.8%)    53 (55.8%)
  Gefitinib                                           40 (42.1%)    18 (45.0%)
  Erlotinib                                           24 (25.3%)    16 (66.7%)
  Icotinib                                            25 (26.3%)    13 (52.0%)
  Afatinib                                            1 (1.1%)      1 (100%)
  Icotinib/gefitinib                                  1 (1.1%)      1 (100%)
  AZD9291/gefitinib                                   1 (1.1%)      1 (100%)
  Unknown                                             3 (3.2%)      3 (100%)
  **Chemotherapy/radiotherapy/treatment na**ï**ve**   24 (20.2%)    10 (41.7%)
  **Total**                                           119           63 (52.94%)

###### 

Mutant allele frequency shown for 63 T790M mutation positive NSCLC patients

  Mutant allele frequency of plasma T790M+ samples   Number                                              Rate   
  -------------------------------------------------- --------------------------------------------------- ------ ---------
  \<0.1%                                                                                                 3      4.76%
  0.1%≤                                              \<0.5%[a](#tfn1-cmar-10-115){ref-type="table-fn"}   23     36.51%
  0.5%≤                                              \<1%[a](#tfn1-cmar-10-115){ref-type="table-fn"}     2      3.17%
  1%≤                                                \<2.5%[a](#tfn1-cmar-10-115){ref-type="table-fn"}   14     22.22%
  2.5%≤                                              \<5%[a](#tfn1-cmar-10-115){ref-type="table-fn"}     5      7.94%
  ≥5%                                                                                                    16     25.40%
  Total                                                                                                  63     100.00%

**Note:**

Stable limits of detection (Sanger sequencing, 5%; ARMS-PCR, 2.5%; Super ARMS-PCR, 1%; Next Generation Sequencing, 0.5%) recorded by Feng et al, unpublished data, 2017.

**Abbreviation:** NSCLC, non-small cell lung cancer.

###### 

Summary of 25 samples of T790M genotyping by 3D Digital PCR

            Mutant allele frequency                Number
  --------- -------------------------------------- --------
  T790M--   --                                     8
  T790M+    Mutant allele frequency \<0.1%         2
            0.1%≤ Mutant allele frequency \<0.5%   8
            0.5%≤ Mutant allele frequency \<1%     --
            1.0%≤ Mutant allele frequency \<2.5%   7

###### 

Comparison results between 3D digital PCR and ARMS-PCR of the 25 samples

                            ARMS-PCR   Total   
  ---------------- -------- ---------- ------- ----
  3D Digital PCR   T790M+   3          14      17
  T790M−           0        8          8       
  Total                     3          22      25

###### 

Triple platform detection results of ten samples

  Sample ID   3D Digital PCR   ARMS-PCR   NGS                         
  ----------- ---------------- ---------- ----- ---- ---------------- -------------
  P1          \+               0.27%      −     \+   0.51%            Wild-type
  P2          \+               0.32%      −     \+   0.54%            19Del 1.24%
  P3          \+               0.24%      −     \+   0.47%            19Del 0.91%
  P4          \+               1.15%      −     \+   1.50%            L858R 2.18%
  P5          \+               1.05%      −          Not enough DNA   
  P6          \+               1.09%      \+                          
  P7          \+               2.09%      \+                          
  P8          \+               2.21%      \+                          
  P9          \+               2.05%      −                           
  P10         \+               1.74%      −                           
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